|
1) Bhatt DL, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006; 295: 180-9
|
|
|
|
2) Joint effects of systolic blood pressure and serum cholesterol on cardiovascular disease in the Asia Pacific region. Circulation. 2005; 112: 3384-90
|
|
|
|
|
|
3) Emberson J, et al. Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Eur Heart J. 2004; 25: 484-91
|
|
|
|
|
|
4) Schwartz JS, et al. Adherence to chronic therapy among patients treated for hypertension, dyslipidemia, or both. J Am Coll Cardiol. 2003; 41: 526
|
|
|
|
|
|
5) Patel BV, et al. Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimen. Vasc Health Risk Manag. 2008; 4: 673-81
|
|
|
|
|
|
6) Blank R, et al. Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin gemini study). J Clin Hypertens (Greenwich). 2005; 7: 264-73
|
|
|
|
|
|
7) Sever P, et al. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J. 2006; 27: 2982-8
|
|
|
|
|
|
8) Dahlof B, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm(ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005; 366: 895-906
|
|
|
|
|
|
9) Messerli FH, et al. Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. J Clin Hypertens (Greenwich). 2006; 8: 571-81; quiz 582-3
|
|
|
|
|
|
10) Cohn JN, et al. Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia. Am J Hypertens. 2009; 22: 137-44
|
|
|
|
|
|
11) Fogari R, et al. Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance. Am J Hypertens. 2004; 17: 823-7
|
|
|
|
|
|
12) Fogari R, et al. Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients. Eur J Clin Pharmacol. 2006; 62: 817-22
|
|
|
|
|
|
13) Trion A, et al. Anti-atherosclerotic effect of amlodipine, alone and in combination with atorvastatin, in APOE＊3-Leiden/hCRP transgenic mice. J Cardiovasc Pharmacol. 2006; 47: 89-95
|
|
|
|
|
|
14) Ogihara T, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res. 2009; 32: 3-107
|
|
|
|
|
|
15) Nakamura T, et al. Pioglitazone exerts protective effects against stroke in stroke-prone spontaneously hypertensive rats, independently of blood pressure. Stroke. 2007; 38: 3016-22
|
|
|
|
|
|
16) Nakamura T, et al. Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan. Hypertension. 2008; 51: 296-301
|
|
|
|
|
|
17) Fukuda M, et al. Potentiation by candesartan of protective effects of pioglitazone against type 2 diabetic cardiovascular and renal complications in obese mice. J Hypertens. 2010; 28: 340-52
|
|
|
|
|
|
18) Yamamoto E, et al. Pravastatin enhances beneficial effects of olmesartan on vascular injury of salt-sensitive hypertensive rats, via pleiotropic effects. Arterioscler Thromb Vasc Biol. 2007; 27: 556-63
|
|
|
|
|